October 21, 2014 4:49 PM ET


Company Overview of Galena Biopharma, Inc.

Company Overview

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company’s lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical ...

4640 SW Macadam Avenue

Suite 270

Portland, OR 97239

United States

Founded in 2003

60 Employees



Key Executives for Galena Biopharma, Inc.

Chief Executive Officer and President
Age: 59
Total Annual Compensation: $490.0K
Chief Financial Officer
Age: 44
Total Annual Compensation: $236.0K
Chief Medical Officer and Executive Vice President
Age: 66
Total Annual Compensation: $127.3K
Compensation as of Fiscal Year 2013.

Galena Biopharma, Inc. Key Developments

Galena Biopharma, Inc. - Special Call

To discuss the company's responses to the recommendations and provide an update on Abstral(fentanyl) sublingual tablets and the status of NeuVax (nelipepimut-S) enrollment

Galena Biopharma, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Galena Biopharma, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Galena Biopharma Provides Update on Phase 2 Clinical Trial

Galena Biopharma, Inc. announced the first patient has been dosed in the GALE-401, or Anagrelide Controlled Release (CR), Phase 2 Clinical Trial. The Phase 2 study will treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET). Based on discussions with the U.S. Food and Drug Administration (FDA) and pending a successful development program, Galena would pursue approval via the 505(b)(2) regulatory pathway. The Phase 2 trial is an open-label, single-arm, multicenter study of GALE-401 in 20 patients with MPN-related thrombocytosis. The goals of the study are to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure blood levels of the drug. The primary efficacy endpoint will be the proportion of subjects who achieve a complete or partial platelet response for at least four weeks during the first six months of treatment. MPNs encompass a family of diseases including essential thrombocythemia, polycythemia vera, primary myelofibrosis, and chronic myelogenous leukemia. The active ingredient immediate release version of anagrelide has been shown to reduce excessive platelet counts and has been approved by the FDA for treating high platelet counts in patients with MPNs. Anagrelide CR is Galena's new formulation of anagrelide that releases the active ingredient more slowly over time than currently marketed versions of this drug, and is therefore absorbed more slowly into the bloodstream.

Similar Private Companies By Industry

Company Name Region
Genentech USA, Inc. United States
Conkwest, Inc. United States
Mx Biodevices, LLC United States
Healionics Corporation United States
Kim Laboratories, Inc. United States

Recent Private Companies Transactions

January 13, 2014
Mills Pharmaceuticals, LLC

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Galena Biopharma, Inc., please visit www.galenabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.